Literature DB >> 163794

Genital herpesvirus hominis infection in mice. I. Development of an experimental model.

J C Overall, E R Kern, R L Schlitzer, S B Friedman, L A Glasgow.   

Abstract

Pregnant female mice, after intravaginal inoculation with Herpesvirus hominis (HVH) type 2, developed vaginitis on days 5 to 7 after virus challenge, followed by hunching and hind limb paralysis on days 7 to 9 and death from encephalitis on days 9 to 11. After initial replication in the mucous membranes of the genital tract, virus spread to the spinal cord and ascended to involve the brain. Viremia or replication of H. hominis type 2 in the liver or spleen was not detected. Virus was cleared from vaginal secretions by days 8 to 10 after infection. Pregnant mice were more susceptible to the infection than nonpregnant mice. This experimental infection in female mice provides a model for genital herpesvirus infection and for herpesvirus infection and for herpesvirus encephalitis in which one can evaluate potentially promising antiviral chemotherapeutic agents.

Entities:  

Mesh:

Year:  1975        PMID: 163794      PMCID: PMC415089          DOI: 10.1128/iai.11.3.476-480.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Factors Modifying Host Resistance to Virus Infection: II. Enhanced Susceptibility of Mice to Encephalomyocarditis Virus Infection During Pregnancy.

Authors:  P A Farber; L A Glasgow
Journal:  Am J Pathol       Date:  1968-09       Impact factor: 4.307

Review 2.  Herpesvirus hominis infection of the female genital tract.

Authors:  G Poste; D F Hawkins; J Thomlinson
Journal:  Obstet Gynecol       Date:  1972-12       Impact factor: 7.661

Review 3.  Infection with herpes-simplex viruses 1 and 2. 1.

Authors:  A J Nahmias; B Roizman
Journal:  N Engl J Med       Date:  1973-09-27       Impact factor: 91.245

4.  Latent herpes simplex virus in spinal ganglia of mice.

Authors:  J G Stevens; M L Cook
Journal:  Science       Date:  1971-08-27       Impact factor: 47.728

5.  Genital herpesvirus hominis type 2 infection: an experimental model in cebus monkeys.

Authors:  A J Nahmias; W T London; L W Catalano; D A Fuccillo; J L Sever; C Graham
Journal:  Science       Date:  1971-01-22       Impact factor: 47.728

6.  Genital herpesvirus hominis Type 2 infection of monkeys.

Authors:  W T London; L W Catalano; A J Nahmias; D A Fuccillo; J L Sever
Journal:  Obstet Gynecol       Date:  1971-04       Impact factor: 7.661

7.  Depressed maternal lymphocyte response to phytohaemagglutinin in human pregnancy.

Authors:  D T Purtilo; H M Hallgren; E J Yunis
Journal:  Lancet       Date:  1972-04-08       Impact factor: 79.321

8.  Effect of adenine arabinoside on severe Herpesvirus hominis infections in man.

Authors:  L T Ch'ien; N J Cannon; L J Charamella; W E Dismukes; R J Whitley; R A Buchanan; C A Alford
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

9.  Idoxuridine in herpes simplex virus (type 1) encephalitis. Experience with 29 cases in Michigan, 1966 to 1971.

Authors:  D C Nolan; C B Lauter; A M Lerner
Journal:  Ann Intern Med       Date:  1973-02       Impact factor: 25.391

10.  Effect of pregnancy and hypertension on reticuloendothelial activity.

Authors:  B H Douglas; J B Grogan
Journal:  Am J Obstet Gynecol       Date:  1970-05-01       Impact factor: 8.661

View more
  24 in total

1.  Protective effect of an oral infection with herpes simplex virus type 1 against subsequent genital infection with herpes simplex virus type 2.

Authors:  B Sturn; K E Schneweis
Journal:  Med Microbiol Immunol       Date:  1978-07-04       Impact factor: 3.402

2.  Alteration of mortality and pathogenesis of three experimental Herpesvirus hominis infections of mice with adenine arabinoside 5'-monophosphate, adenine arabinoside, and phosphonoacetic acid.

Authors:  E R Kern; J T Richards; J C Overall; L A Glasgow
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

3.  Pathogenesis of herpes simplex virus types 1 and 2 in mice after various routes of inoculation.

Authors:  H E Renis; E E Eidson; J Mathews; J E Gray
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

4.  Resistance to vaginal or systemic infection with herpes simplex virus type 2.

Authors:  M C Breinig; L L Wright; M B McGeorge; P S Morahan
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

5.  Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs.

Authors:  L R Stanberry; S Kit; M G Myers
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

6.  Herpes simplex virus type 2 infection of neonatal mice.

Authors:  D A Baker; S A Plotkin
Journal:  Infection       Date:  1978       Impact factor: 3.553

7.  Treatment of experimental herpesvirus infections with phosphonoformate and some comparisons with phosphonoacetate.

Authors:  E R Kern; L A Glasgow; J C Overall; J M Reno; J A Boezi
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

8.  Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection.

Authors:  Jill M Steinbach; Caroline E Weller; Carmen J Booth; W Mark Saltzman
Journal:  J Control Release       Date:  2012-06-15       Impact factor: 9.776

9.  Comparative activities of selected combinations of acyclovir, vidarabine, arabinosyl hypoxanthine, interferon, and polyriboinosinic acid-polyribocytidylic acid complex against herpes simplex virus type 2 in tissue culture and intravaginally inoculated mice.

Authors:  L R Crane; D A Milne; J C Sunstrum; A M Lerner
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Jane E Strasser; Nicholas Farley; Claudia Chalk; Marla Lay; Jeff Fairman
Journal:  Clin Vaccine Immunol       Date:  2009-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.